Skip to contentV
Vitaspring Biomedical Co. Ltd.
V
VSBCVitaspring Biomedical Co. Ltd. Q3 2024 · 10-Q
Revenue$0.00$0.00— vs Q3 2023 Net Income-$234.98K-$234.98KN/M vs Q3 2023 EPS Diluted$0.00$0.00— vs Q3 2023 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vitaspring Biomedical Co. Ltd. · CIK 1697884 · Engraved from SEC EDGAR
-$234,980
N/M
Operating Cash Flowderived-$4,545N/M ended Oct 31, 2023 · filed Jan 30, 2026 · 822 d after period end